The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Imaging and Image-directed Interventions
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1420956
This article is part of the Research Topic Advances in Proctology and Colorectal Surgery Volume II View all 5 articles
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Fruquintinib and Tislelizumab for Patients with Microsatellite Stable Colorectal Cancer Liver Metastasis Following Failure of Multiple-Line Therapy
Provisionally accepted
Kanglian Zheng
1
Xu Zhu
1
Liang Xu
1
Guang Cao
1
Chuanxin Niu
1
Xiaoluan Yan
2
Da Xu
2
Wei Liu
2
Quan Bao
2
Li-Jun Wang
2
Kun Wang
2
Bao-Cai Xing
2*
Xiaodong Wang
1*- 1 Department of Interventional Therapy, Beijing Cancer Hospital, Peking University, Beijing, China
- 2 Beijing Cancer Hospital, Peking University, Beijing, Beijing Municipality, China
The prognosis of microsatellite stable (MSS)-colorectal cancer liver metastasis (CRCLM) which failed from multi-line therapy remains dismal. The aim of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) plus fruquintinib and tislelizumab (HAIC-F-T treatment) for MSS-CRCLM which failed from multiple-line therapy. From February 2021 to June 2023, 45 patients with MSS-CRCLM after failure of multiple-line therapy who received HAIC combined with fruquintinib and tislelizumab (HAIC-F-T triple treatment) were enrolled. The combination therapy included HAIC regimens with oxaliplatin and 5-fluorouracil or irinotecan, oxaliplatin, and 5-fluorouracil on days 1-2, intravenous tislelizumab (200 mg) before HAIC on day 1, and oral fruquintinb (3 mg/d) on day 3-21, every 4 weeks. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. The follow-up ended on June 22, 2024, with a median follow-up time of 17.5 months. The objective response rate was 42.2%, and the disease control rate was 82.2%. The median OS was 15.3 months (95% confidence interval [CI]:12.634-17.966), and the median PFS was 7.5 months (95% CI:5.318-9.682). The independent risk factors related to worse OS were previous PD-1 immunotherapy (P = 0.021) and the number of HAIC-F-T triple treatment cycles of ≤ 2 (P = 0.007). The incidence of grade 3 or higher adverse events (AEs) was 20%, with the most frequent grade 3 or higher AEs being abdominal pain (3/45, 6.7%). In conclusion, HAIC combined with fruquintinib and tislelizumab may be an alternative salvage treatment for patients with MSS-CRCLM who failed multiple-line therapy.
Keywords: Colorectal cancer liver metastasis, Microsatellite-stable, Hepatic arterial infusion chemotherapy, fruquintinib, tislelizumab
Received: 21 Apr 2024; Accepted: 29 Jul 2024.
Copyright: © 2024 Zheng, Zhu, Xu, Cao, Niu, Yan, Xu, Liu, Bao, Wang, Wang, Xing and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bao-Cai Xing, Beijing Cancer Hospital, Peking University, Beijing, 100142, Beijing Municipality, China
Xiaodong Wang, Department of Interventional Therapy, Beijing Cancer Hospital, Peking University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.